CLT1 targets angiogenic endothelium through CLIC1 and fibronectin

Angiogenesis

Volumn 15, Issue 1, 2012, Pages 115-129

  Knowles, Lynn M ^a   Malik, Gunjan ^a,b   Hood, Brian L ^a,c   Conrads, Thomas P ^a,c   Pilch, Jan ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Chloride intracellular channel 1; CLT1; Fibronectin; Integrin

Indexed keywords

BINDING PROTEIN; CHLORIDE INTRACELLULAR CHANNEL 1; CYSTYLGLYCYLLEUCYLISOLEUCYLISOLEUCYLGLUTAMYLLYSYLMETHIONYLGLUTAMYLCYSTEINE; FIBRONECTIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CHLORIDE CHANNEL; CLIC1 PROTEIN, HUMAN; CYCLO(CYSTEINYL GLYCYL LEUCYL ISOLEUCYL ISOLEUCYL GLUTAMINYL LYSYL ASPARAGINYL GLUTAMYL CYSTEINYL); CYCLO(CYSTEINYL-GLYCYL-LEUCYL-ISOLEUCYL-ISOLEUCYL-GLUTAMINYL-LYSYL-ASPARAGINYL-GLUTAMYL-CYSTEINYL); CYCLOPEPTIDE;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTERNALIZATION; LIGATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; ANGIOGENESIS; ANIMAL; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENDOCYTOSIS; LYSOSOME; MALE; METABOLISM; MOLECULAR GENETICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CHLORIDE CHANNELS; ENDOCYTOSIS; ENDOTHELIUM, VASCULAR; FIBRONECTINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYSOSOMES; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, QUATERNARY;

EID: 84861557846     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9247-8     Document Type: Article

References (49)

1. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364. doi:S0092-8674(00) 80108-7
2. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5(6):436-446. doi:10.1038/nrc1627
3. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737-744. doi:10.1038/350 36374
4. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285(5430):1028-1032
5. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56(17):4032-4039
6. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62(15):4263-4272
7. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63(14):4009-4016
8. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109. doi:10.1158/0008-5472.CAN-04-1443
9. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6(9):734-745. doi:10.1038/nrd2380
10. Ivy SP, Wick JY, Kaufman BM (2009) An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6(10):569-579. doi:10.1038/nrclinonc.2009.130
11. Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and metaanalysis of clinical trials. Lancet Oncol 10(10):967-974. doi:10.1016/S1470-2045(09)70222-0
12. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285(5435):1926-1928
13. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277-285. doi:S0092-8674(00)81848-6
14. Yi M, Sakai T, Fassler R, Ruoslahti E (2003) Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA 100(20):11435-11438. doi:10.1073/pnas.1635112100
15. Akerman ME, Pilch J, Peters D, Ruoslahti E (2005) Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci USA 102(6):2040-2045. doi:10.1073/pnas.0409844102
16. Morla A, Zhang Z, Ruoslahti E (1994) Superfibronectin is a functionally distinct form of fibronectin. Nature 367(6459): 193-196. doi:10.1038/367193a0
17. Briknarova K, Akerman ME, Hoyt DW, Ruoslahti E, Ely KR (2003) Anastellin, an FN3 fragment with fibronectin polymerization activity, resembles amyloid fibril precursors. J Mol Biol 332(1):205-215. doi:S0022283603008908
18. Hohenester E, Sasaki T, Olsen BR, Timpl R (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 17(6):1656-1664. doi:10.1093/emboj/17.6. 1656
19. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M (2004) Inhibition of angiogenesis by Abeta peptides. Angiogenesis 7(1):75-85. doi:10.1023/B:AGEN. 00000 37335.17717.bf
20. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJ, Grootenhuis PD, Hol WG (1994) The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol 1(1):48-54
21. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW (2003) Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem 278(46):45746-45752. doi:10.1074/jbc.M308608200
22. Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM (2009) Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 106(48):20324-20329. doi:10.1073/pnas.0911281106
23. Pilch J, Franzin CM, Knowles LM, Ferrer FJ, Marassi FM, Ruoslahti E (2006) The anti-angiogenic peptide anginex disrupts the cell membrane. J Mol Biol 356(4):876-885. doi:10.1016/j.jmb. 2005.12.006
24. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349):377-380
25. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163(4):871-878. doi:10.1083/jcb. 200304132
26. Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial/cell- surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68(17):7210-7218. doi:10.1158/0008-5472.CAN-07-6752
27. Pilch J, Brown DM, Komatsu M, Jarvinen TA, Yang M, Peters D, Hoffman RM, Ruoslahti E (2006) Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA 103(8):2800-2804. doi:10.1073/pnas.05112 19103
28. Knowles LM, Yang C, Osterman A, Smith JW (2008) Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 283(46):31378-31384. doi:10.1074/jbc.M803384200
29. Hood BL, Grahovac J, Flint MS, Sun M, Charro N, Becker D, Wells A, Conrads TP (2010) Proteomic analysis of laser microdissected melanoma cells from skin organ cultures. J Proteome Res 9(7):3656-3663. doi:10.1021/pr100164x
30. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, Pilch J (2010) Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res 70(11):4327-4334. doi:10.1158/0008-5472.CAN-09- 3312
31. Yi M, Ruoslahti E (2001) A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci USA 98(2):620-624. doi:10.1073/pnas.98.2.620
32. Goodchild SC, Howell MW, Littler DR, Mandyam RA, Sale KL, Mazzanti M, Breit SN, Curmi PM, Brown LJ (2010) Metamorphic response of the CLIC1 chloride intracellular ion channel protein upon membrane interaction. Biochemistry 49(25):5278-5289. doi:10.1021/bi100111c
33. Kranenburg O, Kroon-Batenburg LM, Reijerkerk A, Wu YP, Voest EE, Gebbink MF (2003) Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett 539(1-3):149-155. doi:S00145 79303002187
34. Menzies FM, Moreau K, Rubinsztein DC (2011) Protein misfolding disorders and macroautophagy. Curr Opin Cell Biol 23(2):190-197. doi:10.1016/j.ceb.2010. 10.010
35. Kumar R, Yoneda J, Bucana CD, Fidler IJ (1998) Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 12(4):749-757
36. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5(9):1032-1038
37. Hill JJ, Tremblay TL, Pen A, Li J, Robotham AC, Lenferink AE, Wang E, O'Connor-McCourt M, Kelly JF (2011) Identification of vascular breast tumor markers by laser capture microdissection and label-free LC-MS. J Proteome Res 10(5):2479-2493
38. Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, Jiang L, Curmi PM, Breit SN, Duchen MR, Mazzanti M (2008) CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia. J Neurosci 28(45): 11488-11499. doi:10.1523/JNEUROSCI.2431-08.2008
39. Tung JJ, Kitajewski J (2010) Chloride intracellular channel 1 functions in endothelial cell growth and migration. J Angiogenes Res 2:23. doi:10.1186/2040-2384-2-23
40. Tung JJ, Hobert O, Berryman M, Kitajewski J (2009) Chloride intracellular channel 4 is involved in endothelial proliferation and morphogenesis in vitro. Angiogenesis 12(3):209-220. doi:10.1007/s10456-009-9139-3
41. Ruoslahti E (1984) Fibronectin in cell adhesion and invasion. Cancer Metastasis Rev 3(1):43-51
42. Magnussen A, Kasman IM, Norberg S, Baluk P, Murray R, McDonald DM (2005) Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 65(7):2712-2721. doi:10.1158/0008- 5472. CAN-04-2691
43. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23(1):33-42
44. Norambuena A, Schwartz MA (2011) Effects of integrin-mediated cell adhesion on plasma membrane lipid raft components and signaling. Mol Biol Cell 22(18):3456-3464. doi:10.1091/mbc.E11-04-0361
45. Gan B, Yoo Y, Guan JL (2006) Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. J Biol Chem 281(49): 37321-37329. doi:10.1074/jbc.M605241200
46. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffioen AW (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70(15):6216-6224. doi:10.1158/0008-5472. CAN-09-4150
47. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103(43):15975-15980. doi:10.1073/pnas.0603883103
48. Belloni D, Veschini L, Foglieni C, Dell'Antonio G, Caligaris- Cappio F, Ferrarini M, Ferrero E (2010) Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res 316(6):1010-1018. doi:10.1016/j.yexcr.2009.11.005
49. Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S (2007) Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109(11):4793-4802. doi:10.1182/blood-2006-11-059 352